Table 1 Patient characteristics at baseline, Follow-up #1 and Final Follow-up.
Patient characteristics | Baseline % (n) | Follow-up #1 % (n) | Final Follow-up % (n) |
|---|---|---|---|
>65 years | 64.2 (5337/8317) | 60.5 (4440/7341) | 62.3 (2286/3670) |
Prior hip fracture | 1.8 (152/8366) | 2.6 (187/7344) | 2.4 (87/3667) |
Prior wrist fracture | 4.2 (353/8367) | 5.3 (392/7345) | 4.9 (180/3665) |
Prior spine fracture | 5.8 (486 (8365) | 6.6 (481/7339) | 7.1 (259/3663) |
High risk patients | 76.0 (6367/8376) | 75.7 (5569/7354) | 78.2 (2871/3673) |
BMD tests | Â | Â | Â |
None | 36.8 (3079/8317) | 33.8 (2479/7328) | 24.7 (902/3657) |
Normal | 17.8 (1490/8317) | 17.7 (1295/7328) | 19.3 (704/3657) |
Osteopenia | 24.2 (2028/8317) | 31.1 (1272/7328) | 35.9 (1313/3657) |
Osteoporosis | 21.2 (1774/8317) | 17.4 (1272/7328) | 20.2 (738/3657) |
Any therapy | 38.3 (3210/8376) | 39.4 (2984/7354) | 43.5 (1596/3673) |
Risedronate | 10.8 (908/8376) | 13.7 (1008/7354) | 19.9 (732/3673) |
Alendronate | 12.5 (1050/8376) | 13.3 (979/7354) | 13.0 (479/3673) |
Etidronate | 7.1 (597/8376) | 5.9 (430/7354) | 5.0 (182/3673) |
Hormone replacement | 6.3 (509/8025) | 5.5 (389/7106) | 4.3 (155/3605) |
Raloxifene | 2.1 (172/8376) | 1.7 (123/7354) | 1.6 (60/3673) |
PTH | 0.1 (6/8376) | 0.0 (3/7354) | 0.2 (7/3673) |
Calcitonin | 1.0 (83/8376) | 0.6 (45/7354) | 0.6 (22/3673) |